OpenAI Revolutionizes Biology with GPT-Rosalind, a Dedicated AI Model
Le brief IA que les pros lisent chaque soir
Les 7 actus IA du jour, décryptées en 5 min. Gratuit.
Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.
Choisis ton rythme
Gratuit · Pas de spam · Désabonnement en 1 clic
OpenAI recently unveiled its latest artificial intelligence model, GPT-Rosalind, which marks a significant advancement in the field of life sciences. This model, named in honor of Rosalind Franklin, renowned for her groundbreaking research on the structure of DNA, is specifically designed to assist scientists in drug discovery, biology, and translational medicine.
Modern scientific research heavily relies on the analysis of complex data. GPT-Rosalind is designed to efficiently sift through this data, thereby reducing the time required to develop and approve new drugs. According to OpenAI, the drug development and approval process in the United States can take between 10 and 15 years. The model aims to optimize target selection for research and formulate robust hypotheses for higher-quality experiments.
The model has been tested in fields such as organic chemistry, proteins, and genetics. It provides researchers with the ability to find relevant scientific publications and design innovative experiments. OpenAI is not alone in this endeavor: Google DeepMind has also developed AI models for scientific research, such as AlphaFold, which contributed to winning part of the 2024 Nobel Prize in Chemistry.
Anthropic also launched Claude for Life Sciences in January, pursuing similar goals. However, the rapid integration of AI into the scientific field raises concerns. Some scientists warn about vulnerabilities and potential misuse risks. OpenAI assures that GPT-Rosalind is equipped with safeguards to prevent malicious uses, such as the creation of biological weapons. The company has collaborated with biotechnology, pharmaceutical, and life sciences organizations to support scientific research.
Sean Bruich, senior vice president of artificial intelligence and data at Amgen, emphasized the importance of accuracy in scientific work. He stated that collaborating with OpenAI allows for the innovative application of their advanced tools, with the potential to accelerate the delivery of medications to patients.
Currently, GPT-Rosalind is accessible only through OpenAI's trusted access system, as a research preview.
Brief IA — L'actualité IA en français
L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.